[144] Guardant Health, Inc. SEC Filing

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) Form 144 shows a proposed Rule 144 sale and recent related transactions by insiders. The filer reports intent to sell 2,000 common shares through Charles Schwab with an aggregate market value of $123,510 and an approximate sale date of 08/21/2025 on NASDAQ. Those 2,000 shares were acquired on 10/01/2024 via the lapse of restricted stock as equity compensation. The filing also discloses a prior sale by Kumud Kalia of 4,000 shares on 06/03/2025 for gross proceeds of $185,562. The notice includes the standard insider representation regarding material undisclosed information and potential 10b5-1 plan disclosure.

Positive

• Full Rule 144 disclosure provided with acquisition dates, broker, and planned sale date indicating regulatory compliance
• Transaction transparency includes both the intended sale and a prior sale with gross proceeds, aiding investor visibility

Negative

• Insider selling activity (2,000 shares planned; 4,000 previously sold) could be viewed negatively by some investors as reduced insider ownership

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice disclosing an insider sale of recently vested restricted shares and a prior sale by a named individual.

This filing documents compliance with Rule 144 for an intended sale of 2,000 shares acquired through a restricted stock lapse on 10/01/2024, to be executed via Charles Schwab on 08/21/2025. It also reports a separate, completed sale of 4,000 shares by Kumud Kalia on 06/03/2025 for $185,562. From a compliance perspective, the filing provides essential transaction dates, acquisition nature, and broker details required under Rule 144; no material undisclosed information is asserted by the seller.

Corporate Governance Specialist

TL;DR: Insider selling of vested equity is disclosed; context suggests routine liquidity rather than employment or control change.

The notice shows equity compensation vesting followed by a planned sale, which is a common executive/employment-related liquidity event. The designations and amounts are clear: 2,000 shares from restricted stock lapse and a prior 4,000-share sale. The filing includes the standard attestation about no material nonpublic information and mention of potential 10b5-1 plans, indicating awareness of trading-plan safe harbors.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	2000	123510.00	124705857	08/21/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2024	Restricted Stock Lapse	Guardant Health, Inc.			2000	10/01/2024	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kumud Kalia 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	06/03/2025	4000	185562.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Guardant Health's Form 144 disclose for GH?

The filing discloses a proposed sale of 2,000 common shares (aggregate market value $123,510) with an approximate sale date of 08/21/2025 on NASDAQ.

How were the 2,000 shares acquired per the Form 144?

The 2,000 shares were acquired on 10/01/2024 via a restricted stock lapse from Guardant Health as equity compensation.

Were there any recent related sales reported?

Yes. The filing lists a prior sale by Kumud Kalia of 4,000 shares on 06/03/2025 for gross proceeds of $185,562.

Which broker is handling the proposed sale?

The proposed sale is to be handled by Charles Schwab & Co., Inc. located at 3000 Schwab Way, Westlake, TX.

Does the filer state there is any undisclosed material information?

By signing, the person represents they do not know any material adverse information about the issuer that is not publicly disclosed.